Tafinlar
Tafinlar-Mekinist Approved for BRAF-Positive Anaplastic Thyroid Cancer
The FDA approved the combination of dabrafenib (Tafinlar, Novartis) and trametinib (Mekinist, Novartis) for the ...
MAY 8, 2018
Tafinlar Plus Mekinist Combo Approved as Adjuvant Rx for BRAF V600-Mutant Melanoma
The FDA has approved the combination of dabrafenib (Tafinlar, Novartis) and trametinib (Mekinist, Novartis) for ...
MAY 1, 2018
Tafinlar + Mekinist, Companion Dx Approved for BRAF V600E–Mutant Metastatic NSCLC
Dabrafenib (Tafinlar, Novartis) in combination with trametinib (Mekinist, Novartis) with Oncomine Dx Target Test ...
JUNE 23, 2017
Load more